Olsalazine
Aminosalicylate — ALIMENTARY TRACT AND METABOLISM
Also known as: azodisalicylate, CJ 91B, dipentum, olsalazine sodium
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Olsalazine is an ofp drug in the Aminosalicylate class catalogued in DrugCentral. It was first approved by the FDA in 1990. DrugCentral lists 4 molecular targets, including BLVRB, ALOX5 and PPARG. Recorded indications include Ulcerative colitis in remission.
- Approval status: ofp (first approved 1990 by the FDA).
- Drug class: Aminosalicylate.
- Molecular targets: BLVRB, ALOX5, PPARG and PTGS1|PTGS2 (4 listed in DrugCentral).
- Indications: Ulcerative colitis in remission.
- ATC code: A07EC03 (Aminosalicylic acid and similar agents).
- Molecular formula: C14H10N2O6; molecular weight 302.24 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (1)
- Ulcerative colitis in remission
Off-label uses (2)
- Crohn's disease
- Ulcerative colitis
Contraindications (5)
- Allergic rhinitis
- Asthma
- Diarrhea
- Disease of liver
- Kidney disease
Mechanism & targets
| Established pharmacologic class | Aminosalicylate |
|---|
Molecular targets (4)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Flavin reductase (NADPH) | BLVRB | unknown | Kd 7.16 |
| Arachidonate 5-lipoxygenase | ALOX5 | inhibitor | — |
| Peroxisome proliferator-activated receptor gamma | PPARG | agonist | — |
| Cyclooxygenase | PTGS1|PTGS2 | inhibitor | — |
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 1990-07-31 | FDA | — | MEDA PHARMS |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
A07EC03 | ALIMENTARY TRACT AND METABOLISM › ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS › INTESTINAL ANTIINFLAMMATORY AGENTS › Aminosalicylic acid and similar agents |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Colitis ulcerative | 57.7 |
Chemical structure
| Molecular formula | C14H10N2O6 |
|---|---|
| Molecular weight | 302.24 g/mol |
| CAS number | 6054-98-4 |
| InChIKey | QQBDLJCYGRGAKP-UHFFFAOYSA-N |
| PubChem CID | 22419 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Olsalazine used for?
DrugCentral lists the following indications for Olsalazine: Ulcerative colitis in remission.
How does Olsalazine work?
Its molecular targets in DrugCentral include BLVRB, ALOX5 (inhibitor), PPARG (agonist) and PTGS1|PTGS2 (inhibitor).
When was Olsalazine first approved?
Olsalazine was first approved by the FDA in 1990.
What drug class does Olsalazine belong to?
Olsalazine is in the Aminosalicylate class.
What is the chemical formula of Olsalazine?
Olsalazine has the molecular formula C14H10N2O6 and a molecular weight of 302.24 g/mol.
Browse: all drugs starting with O · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 1988 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL1201013 — compound record and bioactivity
- PubChem CID 22419 — chemical identifiers
- DrugBank DB00244 — drug record
- FDA UNII ULS5I8J03O — substance identity
- DailyMed: FDA labels for Olsalazine — current prescribing information (label search)
- UniProt P30043 (BLVRB) — target protein
- UniProt P09917 (ALOX5) — target protein
- UniProt P37231 (PPARG) — target protein
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.